Ajooni Biotech Ltd has announced that its newly constructed manufacturing facility is set to commence commercial production within the next 5 to 7 days. The move marks a strategic expansion in its operational capacity, aimed at meeting rising demand in the animal nutrition and health segment. Regulatory filings confirm the update.
Ajooni Biotech Ltd, a key player in the animal feed and nutrition industry, is poised to begin commercial operations at its newly built production plant. The company disclosed this development through a regulatory filing dated October 24, 2025, submitted to both the BSE and NSE under SEBI’s Listing Obligations and Disclosure Requirements.
Notable Updates:
- The new facility is expected to commence production within the next 5 to 7 days, signaling the final phase of commissioning and readiness.
- This expansion is part of Ajooni Biotech’s strategic roadmap to scale manufacturing capabilities and cater to growing market demand across India and international markets.
- The plant is equipped with advanced machinery and automation systems designed to enhance output efficiency and product quality.
- The company anticipates a positive impact on revenue and margins in the upcoming quarters, driven by increased capacity and operational leverage.
- Stakeholders view this development as a strong signal of Ajooni’s commitment to innovation and growth in the biotech and agri-nutrition space.
This milestone reinforces Ajooni Biotech’s position as a forward-looking enterprise focused on sustainable and scalable growth.
Sources: BSE Corporate Filings, NSE Circulars (dated October 24, 2025).